跳到正文
ESMO 2026持续更新

DELLPHI-305

88 篇报道2 个报道来源4 小时前更新

先了解这件事

还没有综述，先看下面的报道时间线。

报道时间线

沿着报道，了解事件的不同侧面。

10月25日
  1. ESMO 2026 现场信号
    Article updated with Day 2 of #ESMO26.
  2. ESMO 2026 现场信号
    Today, the Phase 3 results of DeLLphi-305 (@AmgenOncology @AstraZeneca) were presented by @sands_jacob at #ESMO26.
  3. ESMO 2026 现场信号
    "I fully expect this trial to establish DLL3 TCE as the dominant first line strategy in SCLC and will likely be practice changing." @TejasPatilMD on DeLLphi-305
  4. ESMO 2026 现场信号
    DeLLphi-305: OS-positive phase III.
  5. ESMO 2026 现场信号
    Impressive results of DeLLphi-305 for ES-#SCLC.
  6. ESMO 2026 现场信号
    A standing ovation: Tarlatamab + durvalumab as frontline maintenance in ES-SCLC, phase 3 DeLLphi-305:
  7. ESMO 2026 现场信号
    Breaking from the #ESMO26 Presidential Symposium! 🚨
  8. ESMO 2026 现场信号
    I always get excited by plenaries at major conferences. Today’s DeLLphi-305 results are an example of seeing the standard of care changing to better patients’ lives. Tarlatamab is
  9. ESMO 2026 现场信号
    Proud to share that the primary analysis of the phase 3 DeLLphi-305 trial was presented today at #ESMO2026 in Madrid by Dr. Jacob Sands and simultaneously published in The New Engl
  10. ESMO 2026 现场信号
    Proud to share that the primary analysis of the phase 3 DeLLphi-305 trial was presented today at #ESMO2026 in Madrid by Dr. Jacob Sands and simultaneously published in The New Engl
  11. ESMO 2026 现场信号
    ⬆️
  12. ESMO 2026 现场信号
    On Monday I told a patient with SCLC, this is the treatment plan today, but I’m hoping next week I can bring you better news from #ESMO26
  13. ESMO 2026 现场信号
    Well-deserved standing ovation! The Phase 3 DeLLphi-305 trial showed that adding tarlatamab-dlle to durvalumab maintenance therapy significantly improved OS in lung cancer (ES-SCLC
  14. ESMO 2026 现场信号
    Let’s take a look at #DeLLphi-305: the trial yields poor results in the "Americas," so you bring in a large number of Asian patients (±40%) #sclc #ESMO26 Opinions??? @StephenVLiu
  15. ESMO 2026 现场信号
    Promising results from DeLLphi-305 at #ESMO26!
  16. ESMO 2026 现场信号
    #ScienceLink #Madrid2026 #ESMO26 #DeLLphi305 #Tarlatamab #Durvalumab
  17. ESMO 2026 现场信号
    💃🍷 Eating tapas while watching the TOP #lungcancer abstracts roll in from #ESMO26 in Madrid!
  18. ESMO 2026 现场信号
    Lots of exciting developments at #ESMO26! Several important studies were also published simultaneously in major medical journals. A few highlights:
  19. ESMO 2026 现场信号
    DeLLphi-305 (phase III) #ESMO26.
  20. ESMO 2026 现场信号
    #ESMO26 Presidential 1
  21. ESMO 2026 现场信号
    #ESMO26
  22. ESMO 2026 现场信号
    #ESMO26
  23. ESMO 2026 现场信号
    Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial @sands_jacob . A new chapter in the treatment of ES-SCLC! #ESMO26. One year ago, we anticipated th
  24. ESMO 2026 现场信号
    We kick off our #ESMO26 coverage with the primary analysis of the phase 3 DeLLphi-305 trial presented by @sands_jacob
10月24日
  1. ESMO 2026 现场信号
    I very much enjoyed the discussion by @StephenVLiu of DeLLphi-305 (tarlatamab + durvalumab as maintenance therapy in ES-SCLC at #ESMO26
  2. ESMO 2026 现场信号
    Standing ovation at #ESMO26! 👏
  3. ESMO 2026 现场信号
    🔥 DeLLphi-305 shook the room at #ESMO26 and what a spectacular discussion by @StephenVLiu
  4. ESMO 2026 现场信号
    Great DeLLphi-305 discussion by @StephenVLiu ; let’s not forget the drop off post induction; seems to trump lurbi; ICANS and CRS noted but manageable. #ESMO26
  5. ESMO 2026 现场信号
    DeLLphi-305 delivered the data, but Dr. Stephen Liu DeLLivered the oracle! 🔥
  6. ESMO 2026 现场信号
    Striking results from DeLLphi-305 in SCLC topped with an emotional standing ovation. Mainteinance Tarlatamab is actually more like a second induction-treatment rather than a proper
  7. ESMO 2026 现场信号
    Impressive results from phase III DeLLphi-305 at #ESMO26 @sands_jacob: Adding tarlatamab to durvalumab maintenance in ES-SCLC 1-y OS nearly 80%!!!
  8. ESMO 2026 现场信号
    DeLLphi-305 at #ESMO26, presented by Jacob Sands, got a standing ovation. An important advance in very aggressive biology. Tarlatamab + durvalumab vs durvalumab as 1L maintenance i
  9. ESMO 2026 现场信号
    Expert discussion of DeLLphi-305 by @StephenVLiu. Bringing tarlatamab to maintenance is major advance as second line tarlatamab is often “a promise we cannot keep.”
  10. ESMO 2026 现场信号
    🚨 Impressive results from #ESMO2026!
  11. ESMO 2026 现场信号
    In DeLLphi-305: The combination of Tarlatamab+ Durvalumab improves both OS (21 vs 12 months HR 0.42) and PFS in ES-SCLC. This is remarkable in such a lethal disease with high recur
  12. ESMO 2026 现场信号
    🚨 #ESMO26 | DeLLphi-305 (Phase 3)
Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC after chemo-IO (N=563)
  13. ESMO 2026 现场信号
    💥Game-changer in small cell #lungcancer! #ESMO26 LBA3 DeLLphi-305: Tarlatamab + durvalumab vs durvalumab 1L maintenance in ES-SCLC (n=563) after chemo-IO. Median OS ⬆️ 21.1 vs 12.7
  14. ESMO 2026 现场信号
    Standing ovation at #ESMO2026 for DELLPHI-305. It is heart-warming to see a meaningful survival advantage in ED-SCLC.
  15. ESMO 2026 现场信号
    #ESMO26 | DeLLphi-305
  16. ESMO 2026 现场信号
    A question about DeLLphi-305’s OS curves:
  17. ESMO 2026 现场信号
    DeLLphi-305 shows striking OS benefit with tarlatamab maintenance (HR 0.42).
  18. ESMO 2026 现场信号
    DeLLphi-305 raises a real-world challenge:
  19. ESMO 2026 现场信号
    DeLLphi-305. Immpresive curves . Additional Toxicity and cost in real world needs to be seen . Good for patients with extensive SCLC @myESMO @OncoAlert #esmo26
  20. ESMO 2026 现场信号
    Excited to see the highly anticipated DeLLphi-305 at #ESMO26. First line maintenance tarlatamab + durvalumab improves PFS and OS.
  21. ESMO 2026 现场信号
    🔥 Presidential Symposium I #ESMO26
  22. ESMO 2026 现场信号
    🔥🔥🔥 #ESMO26 DeLLphi-305 in @NEJM
  23. ESMO 2026 现场信号
    Presidential symposium 1️⃣!!
  24. ESMO 2026 现场信号
    Remarkable OS benefit in ES-SCLC! #ESMO26
  25. ESMO 2026 现场信号
    📖 A new chapter in SCLC therapy has been written by @sands_jacob
  26. ESMO 2026 现场信号
    Outstanding presentation by our very own @DanaFarber @sands_jacob ! DeLLphi-305: tarlatamab + durvalumab vs durvalumab as 1L maintenance in ES-SCLC improved median OS to 21.1 vs 12
  27. ESMO 2026 现场信号
    DeLLphi-305; ES-SCLC; nearly 2y mOS; Strong PFS signal; this is about the strongest data I’ve seen in this space. @BTOGORG #ESMO26
  28. ESMO 2026 现场信号
    📖 A new chapter in SCLC therapy has been written by @sands_jacob
  29. ESMO 2026 现场信号
    🚨🔥 ABSOLUTELY STUNNING! DeLLphi-305 at #ESMO26!
  30. ESMO 2026 现场信号
    #ESMO26 | DeLLphi-305
  31. ESMO 2026 现场信号
    DeLLphi-305 @NEJM #ESMO26
  32. ESMO 2026 现场信号
    #ESMO26: Significant improvements in overall survival in the DeLLphi-305 #ClinicalTrial with the bispecific T-cell engager #immunotherapy tarlatamab added to durvalumab could be pr
  33. ESMO 2026 现场信号
    ⭐️ #ESMO26 #LCSM
  34. ESMO 2026 现场信号
    ‼️ Impressive results from DeLLphi-305 (phase III) just out this afternoon #ESMO26.
  35. ESMO 2026 现场信号
    Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial. A new chapter in the treatment of ES-SCLC! #ESMO26
  36. ESMO 2026 现场信号
    Looking forward to the #ESMO26 Presidential Symposium! Exciting DeLLphi-305 data in ES-SCLC, presented by @JacobSandsMD, followed by what promises to be an insightful discussion fr
  37. ESMO 2026 现场信号
    #ESMO26 NEJM
  38. ESMO 2026 现场信号
    The biggest breakthrough in extensive-stage SCLC in decade
  39. ESMO 2026 现场信号
    Presented at #ESMO26:
  40. ESMO 2026 现场信号
    OncoAlert 4Sight Abstracts to be Presented at #ESMO26
  41. ESMO 2026 现场信号
    ⏰️ Coming up at #ESMO26: The first @myESMO Presidential Symposium kicks off at 4:30 PM CEST!
  42. ESMO 2026 现场信号
    WOW! BIG news for our patients with extensive-stage small cell lung cancer!
  43. ESMO 2026 现场信号
    🚨 Major SCLC results at #ESMO26!
  44. ESMO 2026 现场信号
    🔥 TODAY COULD BE ONE OF THE DEFINING MOMENTS OF #ESMO26! 🔥
  45. ESMO 2026 现场信号
    #ESMO2026 #ESMO26 @myESMO
  46. ESMO 2026 现场信号
    DeLLphi-305 (LBA3, #ESMO26): tarlatamab + durvalumab vs durvalumab maintenance in ES-SCLC.
  47. ESMO 2026 现场信号
    #ESMO26 LBA3
  48. ESMO 2026 现场信号
    DeLLphi-305 - tarlatamab added to durvalumab after initial chemo-immunotherapy for small lung cancer essentially doubles survival. Hope for all cancers here, if the right target &a
  49. ESMO 2026 现场信号
    #ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC
  50. ESMO 2026 现场信号
    ⚡️#ESMO26 will round a very busy year for #lungcancer
  51. ESMO 2026 现场信号
    #ESMO26 | DeLLphi-305 – Phase III | Presidential Symposium-1
  52. ESMO 2026 现场信号
    🌐 #ESMO26 Día 1 | 🫁 Pulmón: SCLC y consolidación local en el foco
10月20日
  1. 中文产业新闻
    DeLLphi-305 III 期主要分析入选 2026 ESMO 主席论坛，将披露塔拉妥单抗联合度伐利尤单抗在 ES-SCLC 一线维持的 OS 与 PFS 等数据

    DeLLphi-305 III 期主要分析入选 2026 ESMO 主席论坛（摘要号 LBA3），由 Dana-Farber 癌症研究所 Jacob Sands 教授于 10 月 24 日口头报告塔拉妥单抗联合度伐利尤单抗在广泛期小细胞肺癌一线维持治疗中的 OS、PFS、ORR 具体数据。

本事件热度走势

当前热度 435·可比范围峰值 481（10月25日 06:00）·近 24 小时可比范围变化 +918%·当前参与者 65

参与者计数65
020406080
热度走势
020040060010月20日21:0010月22日10:0010月23日22:0010月25日11:00

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会（CBA）www.cba-usa.org